Palmar-Plantar Erythrodysesthesia and Cytarabine

Letters and Corrections1 April 1985Palmar-Plantar Erythrodysesthesia and CytarabineMARIA R. BAER, M.D., LLOYD E. KING, M.D., Ph. D., STEVEN N. WOLFF, M.D.MARIA R. BAER, M.D.Search for more papers by this author, LLOYD E. KING, M.D., Ph. D.Search for more papers by this author, STEVEN N. WOLFF, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-4-556_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Lokich and Moore (1) have reported the occurrence of the palmar-plantar erythrodysesthesia syndrome in patients receiving continuous infusion chemotherapy. Identical skin toxicity occurs in patients with acute leukemia receiving high-dose cytarabine as intermittent intravenous chemotherapy, and has been correlated with duration of therapy (2). Cytarabine, 3 g/m2 body surface area intravenously over 1 hour every 12 hours for 12 doses, induced pain and erythema of the palms, soles, and extensor surfaces of the hand joints in 7 of 27 patients, beginning on day 2 to 7 of treatment and progressing to bulla formation or simple desquamation (2)....References1. LOKICHMOORE JC. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1984;101:798-800. LinkGoogle Scholar2. HERZIGWOLFFLAZARUSPHILLIPSKARANESHERZIG RSHGCG. High-dose cytosine arabinoside therapy for refractory leukemia. Blood. 1983;62:361-9. CrossrefMedlineGoogle Scholar3. HANDESTEINMCDONOUGHGRECOWOLFF KRDFS. Effects of high-dose cytosine arabinoside. Clin Pharmacol Ther. 1982;31:669-74. CrossrefMedlineGoogle Scholar4. CAPIZZIYANGCHENG RJE. Alteration of the pharmacokinetics of high-dose Ara-C by its metabolite, high Ara-U in patients with acute leukemia. J Clin Oncol. 1983;1:763-71. CrossrefMedlineGoogle Scholar5. DEANSALMONGRIFFITH JSK. Prevention of doxorubibin-induced hair loss with scalp hypothermia. N Engl J Med. 1979;301:1427-9. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Vanderbilt University School of Medicine Veterans Administration Medical Center Nashville, TN 37203 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByRisk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parametersSevere palmar-plantar erythrodysesthesia and aplasia in an adult undergoing re-induction treatment with high-dose cytarabine for acute myelogenous leukemia: a possible drug interaction between posaconazole and cytarabineBullous acral erythema: an additional consideration in the differential diagnosis of pauci-inflammatory subepidermal bullae*Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of expertsAcral Erythema with Oral Methotrexate in a ChildPalmar–plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centreVascular Toxicity of Antineoplastic AgentsPalmar-plantar erythrodysesthesiaHand–foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbineCutaneous fibrosis induced by docetaxelHigh Incidence of Chemotherapy-Induced Acral Erythema in Female Patients with non-Hodgkin's Lymphoma Treated with the Vacop-B RegimenThree Cases of Chemotherapy-induced Acral ErythemaCutaneous drug reactionsTreatment of cytarabine acral erythema with corticosteroidsChemotherapy-induced acral erythemaA Variant of the Chemotherapy-Associated Erythrodysesthesia Syndrome Related to High-Dose CyclophosphamideAcral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusionsPainful red hands: a side-effect of leukaemia therapyHypersensitivity reactions from antineoplastic agentsPalmar-Plantar Skin Changes and CytarabineWIM G. PETERS, M.D., ROEL WILLEMZE, M.D.Cancer Chemotherapy and Skin ChangesNICHOLAS J. VOGELZANG, M.D., MARK J. RATAIN, M.D. 1 April 1985Volume 102, Issue 4Page: 556-556KeywordsArthralgiaBlistersBody surface areaChemotherapyDesquamationErythemaToxicity Issue Published: 1 April 1985 PDF DownloadLoading ...